

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/079428 A1

(51) International Patent Classification:

C07K 7/08 (2006.01) *A61P 35/00* (2006.01)
A61P 3/10 (2006.01) *A61K 47/54* (2017.01)
A61P 9/00 (2006.01) *A61K 38/00* (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2021/052636

(22) International Filing Date:

12 October 2021 (12.10.2021)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2016152.7 12 October 2020 (12.10.2020) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**

[GB/GB]; Granta Park, Great Abington, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(72) Inventors: **BROWN, Giles Albert**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **CONGREVE, Miles Stuart**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **SCULLY, Conor**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **PAUL, Rebecca**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(74) Agent: **STRATAGEM IPM LIMITED**; Meridian Court, Comberton Road, Toft, Cambridge CB23 2RY (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH,

(54) Title: LINEAR APELIN RECEPTOR AGONISTS



(1);

(57) **Abstract:** The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein Q, X, AA¹, AA², AA³, AA⁴, AA⁵, AA⁶, AA⁷, AA⁸, AA⁹, AA¹⁰, AA¹¹, AA¹², AA¹³, R¹ R² and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Apelin receptors.



WO 2022/079428 A1